Insight Molecular Diagnostics (IMDX) Share-based Compensation (2015 - 2026)

Insight Molecular Diagnostics has reported Share-based Compensation for 12 years, with the latest figure at $5.2 million in Q1 2026.

• Quarterly Share-based Compensation rose 999.37% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (up 9354.55% YoY) and the FY2025 annual result came in at $5.8 million, up 163.64% from the prior year.
• Share-based Compensation improved to $5.2 million in Q1 2026 per IMDX's latest filing, from $721000.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $6.5 million in Q3 2025 and troughed at -$1.3 million in Q4 2024.
• A 5-year average of $1.7 million and a median of $834000.0 in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation tumbled 359.09% in 2024, then surged 1344.44% in 2025.
• Over 5 years, Share-based Compensation stood at $2.6 million in 2022, then tumbled by 81.52% to $484000.0 in 2023, then sank by 359.09% to -$1.3 million in 2024, then surged by 157.5% to $721000.0 in 2025, then jumped by 621.22% to $5.2 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $5.2 million, $721000.0, and $6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.